Lower quorum threshold reduces risk of meeting adjournments but is a routine governance update. No immediate trading catalyst.
Price Chart
Executive Summary
Alaunos Therapeutics adopted Second Amended and Restated By-Laws on September 16, 2026, lowering the stockholder meeting quorum requirement from a majority to one-third (1/3) of voting power. The change makes it easier to achieve a quorum for shareholder meetings, reducing the risk of meeting failures due to low turnout. This is a routine governance amendment with no financial impact.
Key Facts
- Board approved Second Amended and Restated By-Laws effective September 16, 2026
- Stockholder quorum reduced from majority to one-third (1/3) of voting power
- Board and committee quorum remains unchanged at a majority
- Other changes are conforming, clarifying, and non-substantive
Financial Impact
No financial impact, governance amendment only
Risk Factors
- None, this is a standard bylaw amendment with no material financial or operational implications
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-393462 |
| Document: tcrt-20260916.htm | 0001193125-26-393462 |
| Document: 0001193125-26-393462-index-headers.html | 0001193125-26-393462 |
| Document: 0001193125-26-393462-index.html | 0001193125-26-393462 |
| Document: 0001193125-26-393462.txt | 0001193125-26-393462 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 7d ago | 8-K | $2.13 | awaiting T+20 | awaiting T+20 | $1.89 (−11.27%) |
Oct 21, 2026 9d ago | 8-K | $3.04 | awaiting T+20 | awaiting T+20 | $1.89 (−37.83%) |
Oct 15, 2026 15d ago | SC 13D/A | $2.63 | awaiting T+20 | awaiting T+20 | $1.89 (−28.14%) |
Oct 15, 2026 15d ago | SC 13D | $2.63 | awaiting T+20 | awaiting T+20 | $1.89 (−28.14%) |
Oct 13, 2026 17d ago | Press Release | $3.03 | awaiting T+20 | awaiting T+20 | $1.89 (−37.62%) |
Oct 13, 2026 17d ago | 8-K | $3.03 | awaiting T+20 | awaiting T+20 | $1.89 (−37.62%) |
Oct 9, 2026 21d ago | 8-K | $1.05 | awaiting T+20 | awaiting T+20 | $1.89 (−80.00%) |
Sep 18, 2026 6w ago | Press Release | $1.20 $2.63 | ▼ −119.17% | ▼ −118.96% | $1.89 (−57.50%) |
Sep 16, 2026 6w ago | 8-K | $1.60 $2.18 | ▲ +36.25% | ▲ +34.79% | $1.89 (+18.12%) |
Jun 29, 2026 17w ago | 8-K | $2.37 $1.94 | ▼ −18.14% | ▼ −17.86% | $1.89 (−20.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers